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Abstract
Background
TheWorld Health Organization recommends intermittent preventive treatment in pregnancy
(IPTp) with sulphadoxine-pyrimethamine (SP) alongside long-lasting insecticide-treated
nets (LLIN) and case management for reducing the risks associated with malaria in preg-
nancy in areas of moderate-to-high transmission in sub-Saharan Africa. Due to increasing
Plasmodium falciparum resistance to SP, the search for alternative drugs or strategies to
control malaria in pregnancy is a priority. We assessed the acceptability among pregnant
women and health providers of intermittent screening and treatment (ISTp) and IPTp with
dihydroartemisinin-piperaquine (DP) as alternative strategies in the context of an un-blinded
clinical trial.
Methods
Qualitative data were collected through ten focus group discussions with women participat-
ing in a randomized controlled trial to evaluate ISTp or IPTp with DP (multi-day regimen)
versus IPTp with SP (single dose) in western Kenya. Individual in-depth interviews were
conducted with 26 health providers working in the trial facilities and trial staff.
Results
Women appreciated the advantages of being tested with a rapid diagnostic test (RDT) at
every ANC visit (although a few women disliked finger pricks) and accepted that they would
not receive any antimalarial when tested RDT-negative. There were differences in women’s
experiences of the efficacy of antimalarials between the trial arms, with more women in the
IPTp-SP arm reporting they had experienced malaria episodes. Side effects were
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experienced among women taking DP and SP. Although women and trial staff reported
adherence to the full DP regimen within the trial, health providers were not confident that
women would adhere to multi-day regimens in non-trial settings. Health providers recog-
nized the advantages of ISTp in reducing unnecessary exposure to drugs, but lacked confi-
dence in the reliability of RDTs compared to microscopy.
Conclusions
Our findings indicate that, within a trial context, ISTp-DP and IPTp-DP were generally
acceptable among both users and providers and were regarded as potentially valuable
alternatives to IPTp-SP. Several challenges were identified the most important of which
was concerns with achieving adherence to DP in non-trial settings, requiring operational
feasibility studies in routine health systems. Policy adoption of ISTp with RDTs would
require a major shift in thinking among health providers due to lack of confidence in RDTs.
Background
Malaria infection in pregnancy is associated with severe maternal anemia, placental parasitae-
mia, low birth weight, and increased perinatal mortality. The World Health Organization
(WHO) recommends intermittent preventive treatment in pregnancy (IPTp) with sulphadox-
ine-pyrimethamine (SP) at every scheduled ANC visit in the second and third trimester along-
side long lasting insecticide-treated nets (LLIN) and case management for reducing the risks
associated with malaria in pregnancy. Although SP currently appears to remain effective for
IPTp in pregnant women [1] unlike in children, most likely because they have more immunity
than young children [2], it will be important for countries to monitor the continued effective-
ness of IPTp-SP in this population.
In the face of increasing Plasmodium falciparum resistance to SP [3] and reduced effective-
ness of IPTp-SP in some settings [4, 5], the search for alternative drugs for IPTp and alternative
prevention strategies to control malaria in pregnant women is a priority. A number of multi-
centre clinical trials of alternative drugs for IPTp and alternative strategies to prevent malaria
in pregnancy have been conducted under the auspices of the Malaria in Pregnancy Consortium
[6–8]. One potentially suitable alternative to SP for IPTp is dihydroartemisinin-piperaquine
(DP) due to the long half-life of piperaquine and safety profile in pregnant women [9]. An
alternative prevention strategy to the current policy of IPTp-SP being explored is ‘intermittent
screening and treatment in pregnancy’ (ISTp), whereby women are tested for malaria parasites
with rapid diagnostic tests (RDTs) at every scheduled ANC visit and those found to be positive
are treated with an antimalarial [10]. Women who test negative therefore do not receive any
antimalarial, unlike IPTp where antimalarials are given presumptively. Screening and treat-
ment of pregnant women at first ANC visit (only) is practiced in some but not all health facili-
ties in western Kenya, followed by IPTp-SP in subsequent visits in the second and third
trimester.
A three-arm randomised controlled trial to compare ISTp or IPTp with DP versus current
policy of IPTp-SP in an area of high SP resistance in western Kenya (ClinicalTrials.gov number
NCT01669941) has recently been completed [9]. Nested within the main trial, we assessed the
acceptability among pregnant women and health providers of ISTp-DP and IPTp-DP as alter-
natives to IPTp-SP. The findings will be used to inform implementation should either strategy
be recommended for policy.
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Methods
Ethics Statement
The study was approved by the ethical committees of the Kenya Medical Research Institute’s
(KEMRI) National Ethics Review Committee, Kenya; the Liverpool School of Tropical Medi-
cine, UK; the London School of Hygiene and Tropical Medicine, UK; and the Centres for Dis-
ease Control and Prevention, Atlanta, Georgia, USA. With participants’ prior agreement,
verbal consent was obtained and recorded prior to the focus group discussions. In Kenya preg-
nant women aged 15–17 years are considered emancipated minors and were consented
directly. All ethics committees and institutional review boards approved verbal informed con-
sent to be obtained from FGD study participants and approved the study with the prior knowl-
edge that minors aged between 15–18 years would be consenting for themselves. During
transcription, any names were replaced with codes to ensure anonymity and digital recordings
were deleted once transcription and translation were completed and quality approved.
Study site and trial context
The qualitative study was conducted in the sites of the main trial in Siaya County, western
Kenya, which was conducted between August 2012 and June 2014 [9]. Eligible women<32
weeks gestation attending for scheduled focused antenatal care (ANC) visits during their sec-
ond and third trimester were randomly allocated to receive either: (1) IPTp with SP, (2) IPTp
with a 3-day regimen of DP, or (3) scheduled screening with an RDT at every ANC visit and
treatment of RDT-positive women with a 3-day regimen of DP. Women receiving IPTp-SP
received a single dose of three tablets of SP taken under observation by trial staff. For women
receiving DP for either IPTp or IST, the number of tablets administered was dependent upon
the woman’s weight (range 2–4 tablets per dose). The first dose was administered under obser-
vation and the remaining two doses were taken home. A 5ml venous blood sample was col-
lected for routine and study specific testing including haemoglobin levels, malaria (microscopy
and polymerase chain reaction), HIV, and syphilis. All enrolled women received a long-lasting
insecticide-treated net (LLIN) and were instructed on how to use them.
Trial participants were required to make 2–4 scheduled visits, depending on the gestational
age at enrolment, at intervals of 4–8 weeks apart until delivery. Every fifth participant attending
scheduled ANC visits was visited at home two days after their visit to assess drug safety, adher-
ence and LLIN use. Trial participants were not responsible for any costs of ANC services
received during the trial, including ANC registration, all drugs and tests, delivery and any in-
patient care. They also received transportation reimbursement for all scheduled and un-sched-
uled ANC visits as well as free health insurance during their participation in the trial.
Participants and study procedures
The acceptability study was conducted between July 2013 and April 2014, beginning 12 months
after the clinical trial commenced. Focus group discussions (FGDs) were held with pregnant
women enrolled in all three arms of the trial in two sites and in-depth interviews (IDIs) were
conducted with trial staff and with health providers working in the four trial hospitals, but not
involved directly in delivering trial interventions.
Focus group discussions with trial participants. FGDs were undertaken with trial partic-
ipants who had completed delivery in the catchment populations of Bondo County Hospital
and Madiany sub-County Hospital. Ten FGDs were conducted with five groups of women pur-
posively selected based on their trial intervention experience, namely women who received: 1)
IPTp-DP; 2) ISTp-DP and who were RDT-negative, 3) ISTp-DP and who were RDT-positive
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at least once, 4) IPTp-SP or 5) a heterogeneous group receiving a mix of strategies (Fig 1). Two
FGDs were conducted for each of these five groups, one in Bondo and one in Madiany. A total
of 120 participants were identified through systematic random sampling from the trial database
using a SAS random number generator to select 12 participants from each of the five interven-
tion groups at each site. Women were contacted at home with the aid of community liaison
staff employed by KEMRI, responsible for following up women at home, and invited to partici-
pate in an FGD held in a central location.
The FGD topic guides explored women’s experiences of ANC services received during the
trial, perceptions of the services received, including blood and malaria tests, antimalarial drugs
and regimens given in the clinic and to take home, and the factors which affected repeat atten-
dance at ANC. The FGDs were conducted in the local language, Dholuo, by KEMRI’s social sci-
entist (FA) and notes on verbal and non-verbal communication taken by a note-taker. FGDs
lasted for approximately 50–90 minutes. All FGDs were digitally recorded and transcribed into
English by FA within 48 hours of completion.
Fig 1. Allocation of trial participants to focus group discussion group by trial arm.
doi:10.1371/journal.pone.0150259.g001
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In-depth interviews with trial staff and MOH staff. In-depth interviews were conducted
with trial staff and health facility staff from each of the four trial sites. Health facility staff were
purposively selected and included the health facility in-charge, two nurses working in ANC
clinic, one laboratory and one pharmacy staff from each facility, and a representative of the
District Health Management Team from each of the four sub-counties. Two trial staff from
each trial site were randomly selected.
One-to-one interviews with staff were conducted in English by FA using a semi-structured
topic guide. Interview themes included: 1) perceptions of ISTp-DP and IPTp-DP versus IPTp-
SP, 2) adaptations to working practices that would be required to implement ISTp-DP and
IPTp-DP were they to become policy, 3) recommendations on factors to be considered to
ensure effective implementation, and 4) perceptions of the feasibility of implementing ISTp-
DP and IPTp-DP in the routine health system setting. Interviews were digitally recorded and
transcribed by FA within 24–48 hours of completion.
Data analysis
The FGD and IDI transcripts were entered into NVivo (QSR International) Version 10 for data
management and analysis. Data from the FGDs and IDIs were coded separately by J Hoyt
(JHo) and J Hill (JH) using a combination of pre-defined themes developed by two authors (JH
and JW) based on the research questions that were developed into an analysis framework for
each data set (FGDs and IDIs), and themes that emerged from the data using content analysis
[11]. Any differences in coding were discussed until consensus was reached.
The analysis framework for the FGDs comprised: treatment seeking behavior related to
malaria in pregnancy (data not shown); access to ANC, as defined by Penchanksy [12] (avail-
ability, accessibility, affordability, accommodation, and acceptability); experiences and percep-
tions of ISTp-DP, IPTp-DP, IPTp-SP and other services received during the trial; adherence to
MiP interventions; and perceptions and experiences of the clinical trial (Fig 2). The analysis
framework for the in-depth interviews comprised: experience and opinions of the trial inter-
vention arms according to the WHO health system building blocks [13]; perceptions of wom-
en’s acceptability of the trial interventions; experience, perceptions and opinions about the
clinical trial (data not shown); and implications for implementation (Fig 3). During data analy-
sis, all study participants were assigned anonymous codes. Women are identified by an individ-
ual respondent number, FGD number and code for the relevant arm of the trial; trial staff and
health providers are identified by a respondent number, cadre and role within the health facil-
ity or trial.
Results
A total of 61 women participated in the FGDs; their characteristics are provided in Table 1.
The participants’ age range was 16–42 years, with an average across the FDG groups of 21–27
years. The majority of participants were married (n = 55; 90%) with between 1 and 9 children.
Just over half the women had attained only a primary school education (n = 33; 54%). The
most common occupations were business, farming and being a housewife.
In-depth interviews were conducted with 28 staff, including: 8 trial staff, 8 ANC staff, 4 lab-
oratory technicians, 4 pharmacists and the District Medical Officer in each sub-county
(Table 2). The main characteristics of the interviewees are provided in Table 3.
Acceptability among trial participants
Experiences and perceptions of IST-DP, IPTp-DP and IPTp-SP. Issues affecting wom-
en’s acceptability of the trial interventions were categorized into four main themes: malaria
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tests, and the perceived benefits, side effects and adherence to the trial antimalarials, and trial
arm (Table 4). Quotations are used selectively to illustrate only some viewpoints to reflect vari-
ability or consensus in the Results; a more comprehensive selection of quotations for each
theme are provided in S1 Table.
Malaria tests: Many women saw the advantages of being tested for malaria at every ANC
visit and not only at first ANC visit or when sick with malaria, although a few women disliked
finger pricks. Women who tested RDT-negative appeared to accept that they did not receive
any antimalarial, not even IPTp-SP. Two women in different arms spontaneously described an
association between the absence of malaria in the blood, or a negative malaria test, and having
taken antimalarials previously, one in the context of the trial (ISTp arm) and one in relation to
treatment seeking for malaria episodes in the non-trial setting (IPTp-DP arm).
“R7: the study participants as I think have more advantages because the usual one when you
go to the clinic and you are tested for malaria only that once for the first time [first ANC
visit] and the rest you will not be tested and maybe you get malaria after you had been tes-
ted. . .therefore sometime you are asymptomatic to malaria and it eats up the baby from the
womb but as for those enrolled in the study you are tested in each and every visit such that
if there are chances that you acquire it afterwards then you can get treatment to prevent
it. . .” IPTpDP FGD1
Fig 2. Analysis framework for focus group discussions with trial participants.
doi:10.1371/journal.pone.0150259.g002
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“R7: . . .I also like the method of blood testing because you may have some hidden diseases such
as malaria, thereafter screening and testing is done and you being treated.” ISTpDP.N FGD8
Antimalarials:Women distinguished between the different trial drugs (antimalarials, folic
acid, iron, vitamins) mostly by colour, name, type of intervention (IPTp and ISTp), and the
number of times per day the drug was to be taken. Some multigravid women recognized that
the antimalarials they received in the trial were different to those taken during their previous
pregnancies. Many women reported that they were very happy with the antimalarials given
because they believed they had helped them and their babies.
“R5: the drugs helped me and I never acquired malaria during pregnancy and even after I gave
birth I had a safe delivery and the baby has not been sick up to this moment.” IPTpDP FGD1
Women’s perception of drug efficacy differed between the trial arms with a few women in
the IPTp-SP arm reporting episodes of malaria whilst taking antimalarials, in one instance this
was a woman who had vomited after taking SP.
“R3: what I like about these drugs [SP] is that they have prevented me from getting malar-
ia. . .and until I gave birth I only had malaria once. . .in my own view they helped me
Fig 3. Analysis framework for in-depth interviews with health providers and trial staff.
doi:10.1371/journal.pone.0150259.g003
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Table 1. Characteristics of trial participants in the focus group discussions.
Site Trial arm FGD
Group
No. of
Participants
(N = 61)
Average
age (range)
Marital
status (n)
Educational
attainment (n)
Occupation (n) Average no.
of children
(range)
Bondo IPTp-DP FGD 1 8 23 (17–26) Married
(7); Single
(1)
Primary school Std 3, 7
(2); Secondary Form
1–4 (6)
housewife (4); business (4) 3 (1–5)
Madiany IPTp-DP FGD 2 8 26 (19–31) Married (8) Primary school Std 6–8
(6); Secondary Form
1–3 (2)
farmers (5); business (3) 3 (1–5)
Bondo IPTp-SP FGD 3 8 24 (20–28) Married
(7); Single
(1)
Primary Std 8 (1);
Secondary Form 2–4
(6); College (1)
business (6); teacher (1);
housewife (1)
1 (1–2)
Madiany IPTp-SP FGD 4 5 27 (21–42) Married (5) Primary Std 7–8 (3);
Secondary Form 2, 4
(2)
farmers (3); business (2) 3 (1–6)
Bondo ISTp-DP
positive
FGD 5 5 25 (19–36) Married (5) Primary Std 7–8 (4);
Secondary Form 4 (1)
housewife (3); business (2) 2 (2–4)
Madiany ISTp-DP
positive
FGD 6 4 22 (19–24) Married
(3); Single
(1)
Primary Std 7–8 (3);
College (1)
business (2); teacher (1);
farmer (1)
3 (1–5)
Bondo ISTp-DP
negative
FGD 7 6 25 (21–38) Married
(5); Single
(1)
Primary Std 8 (3);
Secondary Form 2 (1);
College/ university (2)
student (2); business (1);
farmer (1); housewife (1);
community health worker
(1)
3 (1–9)
Madiany ISTp-DP
negative
FGD 8 6 26 (19–38) Married
(5); Single
(1)
Primary Std 7–8 (3);
Secondary Form 3 (2);
College (1)
student (1); business (2);
farmer (3);
3 (1–6)
Bondo Mixed FGD 9 7 21 (16–30) Married
(6); Single
(1)
Primary Std 5–8 (5);
Secondary Form 2, 4
(2)
student (1); business (1);
housewife (5);
3 (1–7)
Madiany Mixed FGD 10 4 22 (21–23) Married (4) Primary Std 8 (3);
Secondary Form 3 (1)
business (1); farmer (2);
housewife (1)
3 (2–3)
Abbreviations: DP, dihydroartemisinin-piperaquine; FGD, focus group discussion; ISTp, intermittent screening and treatment; SP, sulphadoxine-
pyrimethamine; Std, Standard 1–8 (primary school)
doi:10.1371/journal.pone.0150259.t001
Table 2. Selection of trial staff and health providers for the in-depth interviews.
Cadre Bondo District
Hospital (N = 7)
Madiany sub-district
Hospital (N = 7)
Lwak Mission
Hospital (N = 7)
Siaya District
Hospital (N = 7)
Sampling Total
(N = 28)
Trial staff in ANC 2 2 2 2 Random
selection
8
Facility staff in ANC 2 2 2 2 Random
selection
8
Lab technician in
health facility
1 1 1 1 Only 1 staff in
cadre
4
Pharmacist in health
facility
1 1 1 1 Only 1 staff in
cadre
4
District Medical
Ofﬁcer
1 1 1 1 Only 1 staff in
cadre
4
Study Arms IPTp-SP, IPTp-DP
and ISTp-DP
IPTp-SP, IPTp-DP and
ISTp-DP
IPTp-SP, IPTp-DP
and ISTp-DP
IPTp-SP, IPTp-DP
and ISTp-DP
Abbreviations: DP, dihydroartemisinin-piperaquine; IPTp, intermittent preventive treatment; ISTp, intermittent screening and treatment; SP, sulphadoxine-
pyrimethamine
doi:10.1371/journal.pone.0150259.t002
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Table 3. Health provider and trial staff characteristics.
Profession IDI# Highest professional qualiﬁcation Main tasks performed Gender Years in current
facility
Role in ANC
Y/N
Facility Nurse (2) IDI 1 Diploma in Nursing Works in MCH; family planning Female 10 Yes (MCH)
Nursing Ofﬁcer IDI 2 Diploma in Community Nursing &
Community Health
Oversees activities of other nurses Female 3 Yes
Nurse IDI 3 Kenya registered community health
nurse
General nursing duties Female < 6 months Yes
Nurse IDI 4 Diploma in Nursing In-patient department on maternity
ward
Female 3 Yes
(maternity)
Nursing Ofﬁcer IDI 5 Post graduate diploma in Health
System Management
Oversees activities of others &
general nursing duties
Female 7 Yes (MCH)
Nursing Manager IDI 6 Diploma in Nursing Coordinate activities in MCH dept Female 6 Yes (MCH)
Facility Nurse IDI 7 Enrolled Community Nurse General nursing duties Female 3 Yes
Nursing Manager IDI 8 Degree in Nursing Coordinate activities in MCH dept Female 6 Yes (MCH)
Sister-In-charge IDI 9 Diploma in Nursing Coordinate regional HIV activities Female 5 No
Medical
Superintendant
IDI
10
Degree in Pharmacy Medical Superintendent & in charge
of Pharmacy
Male 7 No
Medical
Superintendant
IDI
11
BSc in Medicine, BSc in Surgery General supervision of entire health
facility
Male 2 No
Medical Doctor IDI
12
Medical Doctor General coordination of activities in
the health facility
Male 10 No
Lab Technician IDI
13
Diploma in Laboratory Technology Coordinates activities in the
laboratory
Male 3 No
Lab Technician IDI
14
Diploma in Medical Laboratory Carries out testing of samples Female 3 No
Lab Technician IDI
15
Diploma in Medical Laboratory Coordinates activities in the
laboratory
Female 3 No
Lab Technician IDI
16
Diploma in Medical Laboratory Coordinates activities in the
laboratory
Male 6 No
Pharmacist IDI
17
Bachelor Degree in Pharmacy Oversees procurement & dispensing
of drugs
Male 2.3 No
Pharmacist IDI
18
Higher Diploma in Pharmacy Dispensing drugs Male 10+ No
Pharmacist IDI
19
Diploma in Pharmacy Dispensing drugs Male 3 No
Pharmacist IDI
20
Diploma in Pharmacy Dispensing drugs & managing
inventory
Male 4 No
Nurse IDI
21
Higher Diploma in Nursing/
Community Health
Screening & enrollment of women in
the study
Female 3 Yes
Nurse IDI
22
Diploma in Nursing Screening & enrollment of women in
the study
Female 3 Yes
Site supervisor IDI
23
Degree in Sociology Supervise overall running of the
study at this site
Female 1 Yes
Nurse IDI
24
Registered Community Health
Nurse
Screening & providing all ANC care Female n/a yes
Study Coordinator IDI
25
Registered Nurse Supervise overall running of the
study at this site
Female 6 Yes
Nurse IDI
26
Diploma in Nursing Screening, enrollment & collecting
samples
Female 3 Yes
Nurse IDI
27
Diploma in Nursing Screening, enrollment & providing all
ANC care
Female 2 Yes
Research Ofﬁcer IDI
28
Higher Diploma in Community
Health & Development
Screening, enrollment & collecting
samples
Female 5 Yes
Abbreviations: ANC, antenatal care; IDI, in-depth interview; MCH, Maternal and child health clinic
doi:10.1371/journal.pone.0150259.t003
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because when I went the first time I took them and the second time I took them I vomited
and then after that I was hit by malaria and so when I went back and they were changed
now I used to take them and never vomited. . .and after this malaria disappeared. . .”
IPTpSP FGD3
Side effects: The most commonly reported side effects from antimalarials were nausea and
vomiting; other less frequently reported side effects included loss of appetite, blackouts, fever
or body pains, weakness, and itching. When asked whether they thought that specific drugs
were responsible for the side effects they were experiencing, many women insisted that they
were caused by the antimalarials given in the trial. Women complained of side effects from
both DP and SP. DP was associated with vomiting, nausea, loss of appetite, dizziness and black-
outs, whereas SP was associated with nausea, vomiting and a bad taste in the mouth. It was
acknowledged that some side effects, such as the blackouts reported by one woman, may have
been due to other conditions experienced in pregnancy, such as ‘low blood levels’ (anaemia),
and not DP as had been suggested. One woman in the IPTp-DP arm stated that she believed
the side effects she experienced were due to not eating before taking the drugs.
“R3: because when you are pregnant you can experience a blackout and this sometimes may
mean that the level of blood in your body is very low and the fact that the blood level is low
also means that the two of you are sharing the blood.” IPTpDP FGD2
Table 4. Experiences and perceptions on the acceptability of IPTp-DP or IST-DP vs IPTp-SP among trial participants, trial staff and health
providers.
Themes Pregnant women Health providers/trial staff
Sub-themes Sub-themes
Malaria tests Advantages of being tested every time; Understood that RDT-
negative means no medication
Concerns about speciﬁcity and sensitivity of RDTs; RDTs could
be useful in some settings (when no lab present); RDTs could
reduce wait times for women & provide fast results; Multigravid
RDT-negative women still expect antimalarial
Beneﬁts or efﬁcacy
of antimalarials
Noticed difference in antimalarials given during trial vs
previous pregnancies; Took [IPTp] SP but still got malaria;
Believed the antimalarials had helped them & their babies
Concerns about SP resistance; Women taking DP in the trial
had less malaria than those on SP; IPTp-SP has reduced the
incidence of malaria in pregnancy
Side effects of
antimalarials
Nausea & vomiting with DP; Nausea, vomiting & bad taste
from SP; DP caused blackouts; Some “side effects” may be
due to other conditions
DP caused unpleasant side effects in some women; SP caused
side effects; SP has a high sulfa content that causes allergic
reactions in some women
Adherence to
antimalarials
Women took the antimalarials as prescribed in the trial;
Complained that (adhering to) DP regimen was a ‘difﬁcult’
experience
Concerns about adherence to DP as only ﬁrst dose is given
under DOT; Poor adherence to drugs given to take home;
Lengthy dosing regimens decrease adherence; DP tablets are
too big; Women prefer SP because you only take it for one day;
Women stop taking meds when they start to feel better, or give
medications to friends & family; Information needs to be given
about importance of completing the dose; Information about
timing of taking drugs must be easy for women to follow
IPTp-DP or ISTp-DP
vs IPTp-SP
ISTp: Women were happy to know their malaria status at each
ANC visit
ISTp: Good to treat those with malaria, reduce unnecessary
medication; Concerns about the availability of RDTs and drugs
(DP); Women who test negative don’t get drugs and they are
not satisﬁed; Repeat screening requires women to make repeat
ANC visits; Repeat screening may discourage some women
from attending ANC. IPTp-SP: Concerns about SP resistance;
Lack of RDT sensitivity means some women remain
parasitaemic; need for hybrid strategy (ISTp and IPTp)
Abbreviations: DP, dihydroartemisinin-piperaquine; IPTp, intermittent preventive treatment; ISTp, intermittent screening and treatment; SP, sulphadoxine-
pyrimethamine
doi:10.1371/journal.pone.0150259.t004
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Adherence: Women reported taking most of the drugs given to them during their ANC vis-
its, except for iron and folic acid, which many women said they disliked. They seemed content
taking the antimalarials and respected the dosage and timing.
“R1: I swallowed. . .I was given nine. On the spot I swallowed three, the following day I swal-
lowed three and the third day I swallowed three.” IPTpDP FGD1
A few women were hesitant and voiced concern about the DP regimen, as illustrated in the
following quote, but the vast majority of women receiving DP for either ISTp or IPTp said that
they adhered to the 3-day regimen.
“M: Respondent two, did you take the whole dosage?
R2: The other drugs that I was given I used to take because they told us that they will know
when we don’t take the drugs except malaria drugs [DP] that I was not getting but it was dif-
ficult experience [meaning she was reluctant].” ISTpDP POS FGD5
Perceptions and experiences of ANC received during the trial. Women’s perceptions of
the trial interventions were strongly influenced by the trial context. Women’s experiences of
the ANC services received during the trial were said to be far superior to those received in pre-
vious pregnancies or by non-trial participants for a number of reasons, comprising four main
themes: provider attitudes; provider professionalism; increased availability, quality and range
of services; and free services and transportation. Quotations for each theme are provided in S2
Table.
Acceptability among health providers and trial staff
Perceptions of IST-DP, IPTp-DP and IPTp-SP. Issues relevant to the acceptability of
trial interventions among health providers were categorized into similar themes as for women:
malaria tests; antimalarial efficacy, side effects and adherence; and trial arms (IST-DP, IPTp-
DP and IPTp-SP). The themes and sub-themes emerging from health providers are compared
to those from women in Table 4. Quotations for each theme are provided in S1 Table.
Malaria Tests: Across all cadres of health provider there was a strong preference for micros-
copy over RDTs as the ‘gold standard’ for malaria testing due to reliability of the results. Never-
theless, it was recognised that RDTs were useful in some settings, such as in health facilities
with no labs or no power supply. RDTs were seen to have several benefits. The main benefits
reported by ANC staff across all facilities was the reduction in time wasted by women queuing
for lab results, and the results being available within minutes. A pharmacist and a nurse said
this had two advantages, firstly, that women could see and have greater confidence in the result,
and that treatment could be provided on the spot. The main drawback reported by two lab
technicians and a facility in-charge was that RDTs are not specific or sensitive enough to pro-
duce reliable results.
“M: Now what would you think about the use of RDTs for diagnosis of malaria as an alter-
native of blood slides?
R: Okay. In my view the blood slide still remains the gold standard and in my view, a health
facility like this one should and must continue using the slides for diagnosis. . ..” IDI 10—
Medical superintendant
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“R: Okay, for the RDTs, they are there in case of power, electricity black out then they use
RDTs, but it is being recommended that being that it is a District hospital, they should use
the microscopic way of detecting, testing malaria.” IDI 6—Facility nurse
Antimalarials (efficacy and side effects): DP: Facility staff reported limited experience
with administering DP to treat malaria in pregnancy. ANC nurses from two hospitals said DP
was safe to use in pregnancy and was the preferred drug for the treatment of uncomplicated
malaria in pregnancy, and a pharmacist said it was good for use in pregnant women given their
low immunity. A facility in-charge had heard that DP offers longer protection against malaria
and was therefore a good drug to use for prophylaxis. Several providers were awaiting the out-
come of the trial before making any decisions about its efficacy. Two trial staff and one phar-
macist witnessed some unpleasant side effects caused by DP in a few trial participants,
specifically rashes, dizziness and nausea.
SP:Health providers reported routinely giving SP for IPTp and to women who complain of
having malaria but test negative. Two pharmacists and a facility in-charge correctly stated that
SP should not be given to women allergic to sulfa drugs and that it should be given with water
to dilute the sulfa content, in line with policy.
Adherence: Several staff including three ANC nurses and two facility in-charges said adher-
ence decreased for drugs with lengthy dosing regimens, citing quinine and DP. Considering
pregnant women were also given paracetamol, multivitamins, iron and folate, and de-worming
tablets, one ANC staff said women complained of drug ‘overload’. Other factors perceived by
the providers to affect adherence were sharing drugs with family members, or stopping medi-
cation once women started to feel better. Most but not all trial staff thought that women
adhered to the trial antimalarials. One was doubtful and another reported an instance where a
trial participant was given trial antimalarials by her neighbour.
“R: So you see the empty blister packs and you are very happy that they took the drugs. But
then later, there is a client who came to our clinic. And was telling us that she was feeling
sick and was given some tablets by the neighbor, who is a study participant. And the tablets
when we investigated were actually our DP. So probably she just removed them out of the
blister packs and she kept them. . .. So when this neighbor was complaining that she was
sick, then she was given. . . .So she took once and she felt worse. So she carried the drugs to
the clinic . . . So when we checked [the drugs brought by the neighbour] they were actually
our study drugs. . ..There will be challenges but I think there will be challenges that can be
avoided.” IDI 25—Trial staff
Three pharmacists said pregnant women needed very clear instructions on when to take
drugs and explained they had no way of confirming whether women adhered to drug regimens.
One medical superintendent noted that drug timing instructions needed to be clear so they
were trying to discourage the ‘X times a day’ guidance currently given to clients and replace
with specific intervals in hours. Two pharmacists said women should be advised that the dan-
gers of a malaria relapse should they not complete the full regimen were far worse than any
side effects they may experience.
Trial arms: IPTp-SP: Across all facilities, ANC nurses had the perception that IPTp-SP was
effective in reducing malaria incidence when given under directly observed therapy (DOT).
Several participants simply said it was a good strategy without elaborating as to why. One of
the challenges to giving IPTp-SP by DOT was women wanting to take SP with food. Several
nurses expressed concern about their perception of increasing resistance of the malaria parasite
to SP, noting that some mothers taking IPTp-SP still got malaria.
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“M:What do you think about the use of SP for IPTp in pregnant women? R: Mmm.., SP it
was found that some mothers still get malaria. M: Even after using it? R: Even after using it
we found that some of the mothers were still having malaria so I don’t know the feeling the
people holding the study would have but that’s why they came with other drugs on trial.”
IDI 7—Facility nurse
IPTp-DP: Perceptions of IPTp-DP among trial staff were that there was a lower incidence
of malaria in this arm, with more women testing malaria negative at the monthly visits com-
pared to the IPTp-SP arm. A medical superintendent commented that DP was safe to use in
the 2nd and 3rd trimesters, gave longer acting protection, and would be a good alternative to SP,
concluding that the trial would provide important evidence. Several trial staff however voiced
concerns about adherence to DP since only the first dose is given by DOT.
“M: Did you ever hear the ANC staff employed by the government talking about the trial
interventions? R: And sometimes when they also hear that we give it for three days. I have
heard them asking questions that “will they take it” because I think in this society and envi-
ronment people are not good at taking medications. Yeah, sometimes in the clinic, like SP
you give it as DOT. You observe. Yeah, but if you give them the SP to go with home, some
of them will not even take. So you would hear those raising questions but in all with time we
continue talking to them and when it is a policy, I think all these will be looked at by the
time it is put as a policy.” IDI 25—Trial staff
ISTp-DP: A clear benefit of ISTp reported by two ANC nurses, a medical superintendent
and a pharmacist was that treating only active cases of malaria reduced unnecessary exposure
to antimalarials in pregnancy, with infected women receiving appropriate treatment with an
ACT as opposed to prophylaxis with SP. The medical superintendent also observed that ISTp
was less likely to encourage the development of drug resistance. When asked what they thought
about screening women at every ANC visit (as opposed to current policy, which is only at 1st
ANC visit) there were some practical concerns over the availability of RDTs, the cost and sus-
tainability of scaling-up, and that the strategy relied on women making at least four ANC
visits.
“M: How would you feel about every pregnant woman being given an RDT test at every
ANC visit and if they are were found positive for malaria they would be given an anti-malar-
ial drug. If they were negative they would not receive any anti-malarial? R: Yeah. When we
get there it would be okay. . ...RDTs are expensive. . . And if they are available. . . that is a
good intervention. Okay. We are also aware that the coverage of even the ANC attendance
as we talk about people who have attended for four visits, we still have challenges. But on
the other hand, if the RDTs were available, then we will protect the drugs which. . . we will
protect the drugs we have from being misused because it is only those women who will have
a positive RDT to be given the anti-malarial. But from the public health point of view, the
expense that goes with a program like that needs to be given consideration to vis a vis the
current practice. So if it is something that can be sustained, and the effect can impact posi-
tively towards the burden, alleviating the burden of malaria in pregnancy. Then it will be
okay.” IDI 12- Medical superintendent
One trial staff remarked that women, particularly multigravida women, would need regular
counselling about repeated testing at every ANC visit. Given the lack of reliability of the RDT
results, the medical superintendent was concerned that RDT-negative women would not
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receive antimalarials, and observed that women with false positive tests would be given antima-
larials even if they didn’t have parasites.
ISTp vs IPTp:When asked explicitly which strategy they preferred, IPTp or ISTp, health
providers and trial staff often answered ambiguously. Although they accepted the idea of
screening and treatment, most thought that prevention (IPTp) was also necessary. There was
strong support across cadres, including trial staff, ANC nurses and one pharmacist, for con-
tinuing with prevention using IPTp.
“M: So out of the two we have IPTp and screening. In your opinion, which one do you think
is better? R: Screening and IPTp? M: Yeah. R: I think all of them are better. We should
screen and we should at least give prophylaxis. You know you can come and we give pro-
phylaxis then maybe you are sick and I give you SP. It will not help you unless I screen and
test you to know whether you have malaria, then I give you the drug which is going to help
you.” IDI 4—Facility nurse
One trial staff commented that ISTp-DP was a good strategy because women who tested
positive would be convinced of the need to take an antimalarial (DP), whereas with IPTp
women do not always see the relevance of taking a drug if they did not have malaria (referring
to IPTp-DP). One of the ANC nurses feared that regular testing for ISTp might deter women
from repeat attendance at ANC.
“M: Based on your experience, what do you think is the best approach to be used in dealing
with malaria in pregnancy? R: The best approach would be ISTp-DP, reason for me is that if
you to test a mother and she turns positive, if you give her a drug she will take because she
would be like I was tested and I had malaria she will have reason to tell, but you see if you
give as in the IPTp-DP, a woman would not see the relevance. Somebody will say I’m not
used taking drugs, I don’t even have malaria, but if you take someone positive, they will take
the drug. However, if you just give, ISTp I think is the best one, it will help the compliance
to be like 100 percent or even 90 percent. And also it would reduce the cost of resources.”
IDI 26—Trial staff
Provider perceptions of women’s acceptability of the trial interventions. Drug prefer-
ences: Trial staff reported that pregnant women complained that the DP tablets were too big
and some women broke the tablets in half. They reported that women noticed the difference in
dosing regimens between DP and SP, with some complaining that taking tablets for three days
was a burden.
“R: You know those who are taking DP, the person will rather go for SP. You know SP are
only three tablets starting. . .. . .., but DP you continue, so it always varies. There are those
who feel like people who are in the SP, have lighter loads, and there are those who feel that
those people who are in the DP are better because DP is a new drug.” IDI 26—Trial staff
Trial staff had mixed experiences of side effects reported by women, with one staff reporting
no side effects from DP and one saying that no-one vomited with DP, whereas another said
some women complained of dizziness and loss of appetite but despite these complaints had
completed the regimen. Side effects from SP mentioned to the trial staff by women included
nausea, vomiting and feeling ‘emaciated’.
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Trial arm preferences: With regard strategy preference, trial staff said that some women
preferred to take antimalarials only when sick. Conversely, ANC staff felt that IPTp-SP was
generally well accepted for preventing malaria in pregnancy, as there had been a lot of counsel-
ling, such that if ISTp was introduced, RDT-negative multigravid women might need an expla-
nation as to why they were not receiving an antimalarial.
“M: And how, how do you feel for those who just come and you screened them and unfortu-
nately they are malaria negative, and yet they see others being given the drugs? What can
you say about this? R: It has been a problem, some of them say that why is it that you give so
and so drugs and you do not give me. M: I am going home without. . . R: Without any medi-
cation yet these are people that in other pregnancies they were given the three SP that used
to be given.” IDI 21—Trial staff
Delivering interventions through the ANC platform. Overall, there was more support
for ANC staff dispensing DP for either IPTp or ISTp than against, and this was reflected across
all cadres and all health facilities including lab staff, pharmacists and ANC nurses (S3 Table).
The main reason given in support of ANC staff dispensing antimalarials was that ANC would
provide a one-stop-shop for the ANC package, thereby providing continuity of care and reduc-
ing wait times and queuing at the lab or pharmacy. However, one pharmacist thought ANC
nurses would need to be overseen by a pharmacist to ensure correct practice and for stock man-
agement, given pharmacists are ultimately held responsible for any adverse effects if drugs are
misused.
There was wide support for RDT testing to be performed in ANC clinics in terms of reduced
wait times, faster results, and ensuring that all women are tested and can observe the results. It
was noted that RDTs were low tech, easy to use, and could be easily integrated with HIV test-
ing. Potential disadvantages cited were that regular testing could initially deter women from
repeat ANC attendance, especially if malaria-RDTs were confused with HIV-tests, and that it
would increase the workload of ANC staff. However, one ANC nurse noted that the benefits of
using RDTs to screen women would outweigh the costs of an increased workload.
Discussion
This is the first qualitative study to explore the acceptability among pregnant women and
health providers of IPTp with DP, as a potential replacement drug for SP, and one of several
studies that explores the acceptability of ISTp with either AL [14–17] or DP [18]. The study
was conducted in the context of a clinical trial of IPTp or ISTp with DP vs IPTp-SP in western
Kenya and, although not directly generalizable to a programme setting, provides important
information to inform effective delivery were either of these interventions to become policy.
Acceptability among women who participated in the trial centered on their views and experi-
ences of malaria testing at every ANC visit, and the benefits, side effects and adherence to the
antimalarials received in the trial arms. These views and experiences were heavily influenced
by the trial context in comparison to services multigravid women received in previous preg-
nancies, or compared to non-trial participants attending the same ANC clinics. Although the
health providers interviewed were not directly involved in the trial, many had a good under-
standing of the trial interventions and were aware of women’s experiences in the trial, and their
views and opinions highlight important factors to consider for either strategy.
The majority of women who participated in the trial appreciated the beneficial effects of DP
whether used for IPTp or ISTp, although there were complaints about the lengthy dosing
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regimen, a problem also identified in trials using AL for ISTp [17]. Several women experienced
side effects to DP, though these were mild-to-moderate [19] and were similar to those reported
by women in the SP arm. This mirrors tolerability results from the main trial, with nine docu-
mented episodes of vomiting after taking a study drug in all three trial arms (ISTp-DP -2 cases;
IPTp-DP– 4 cases; and IPTp-SP -3 cases) [9]. This is in contrast to reports from women in a
previous study where nausea and vomiting were more commonly associated with SP than
ACTs [17]. The complaint of side effects occurring because drugs were taken without food was
associated with both DP and SP, though clinical guidelines state that both drugs can be taken
with or without food. The perception that SP must be taken with food has been identified in
observational studies in non-trial settings [20, 21] and has been attributed to low adherence of
IPTp provision by DOT [20, 22]. With regard to ISTp, women appreciated the benefits of
malaria testing at every ANC visit instead of only at the first ANC visit, recognizing that some
infections are asymptomatic yet harmful to the pregnancy. However, a few women were fearful
of finger pricks. Adherence to DP during the trial as reported by women was ‘difficult’ due to
the lengthy regimen and side effects, but they completed the regimen given the strong support-
ive environment of the trial. Health providers were skeptical that this level of adherence could
be achieved in the routine ANC setting, as women are likely to stop taking drugs when they
feel better. This notion is supported by a study in non-pregnant adults in a non-trial setting in
Ghana, which found that adherence was strongest to drugs with minimal or no side effects, and
perceived cure after the initial dose greatly affected adherence [23].
Health providers not involved in the trial reflected many of the views voiced by women.
Facility-in-charges, nurses and pharmacists noted that adherence to the multi-day regimen
and size of DP tablets poses a serious challenge to its future use for either ISTp or IPTp,
although as one trial staff noted, adherence is likely to be higher among women who test posi-
tive in the ISTp strategy as these women will see test result and therefore the relevance of taking
antimalarials. This obstacle was counterbalanced by the view that alternative drugs are needed
in the face of growing resistance to SP. Trial staff were confident that women adhered to the
DP regimen within the trial, but shared the concerns of health providers about replicating
adherence in the routine ANC setting and noted that substantial counselling of women would
be needed. The evidence on adherence to ACTs in the general population is weak, as found in a
systematic review [24], and even less is known about adherence to ACTs during pregnancy
[25], highlighting the need for better quality research to evaluate adherence to ACTs across
diverse contexts using standardised methodologies.
Regarding ISTp, health providers from different cadres acknowledged its main advantage
was limiting treatment to only active cases of malaria thereby reducing unnecessary exposure
to antimalarials, but there were doubts about the reliability of RDTs, similar to studies in non-
pregnant populations [26, 27]. The sensitivity of RDTs in pregnancy is lower than in non-preg-
nant populations [28, 29], and diminishes with increasing gestation (Feiko ter Kuile, personal
communication). The broad skepticism across all cadres about the sensitivity or specificity of
RDTs as a diagnostic method for malaria, and concerns that this strategy would leave some
women unprotected, will need to be addressed should this strategy be recommended for policy.
Overall, the unreliability of RDTs was seen as important as reducing wait times and speeding
up the dispensing of treatment. Although RDT-negative trial participants appeared to accept
not receiving any antimalarial, health providers saw this as a potential challenge among multi-
gravid women who were used to receiving IPTp-SP. Importantly, health providers doubted
that women would attend sufficient ANC visits to ensure monthly RDT-testing, and that ISTp
could deter women who feared testing from coming to ANC. There was a strong preference for
the continuation of IPTp across all cadres, even if ISTp were introduced as part of a hybrid
strategy.
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The acceptability of IPTp-DP and ISTp-DP among women and health providers was clearly
influenced by the trial context, which raises some key issues to be considered when introducing
either strategy into national programmes. Women in the trial appreciated the positive and
helpful attitudes of the trial staff, the comprehensiveness, quality and availability of the care
they received, and the fact that all services were free and transport reimbursement were pro-
vided, a finding consistent with the trial in Ghana [14]. These ANC experiences were in stark
contrast to the services women received from routine ANC in their previous pregnancies.
These factors will have directly encouraged women not only to return for their scheduled ANC
visits, but also to accept aspects of care that they were not entirely comfortable with, such as
regular testing and multi-day drug regimens. It remains to be seen whether this level of ANC
attendance can be replicated and sustained in the non-trial setting, whether it is feasible to
deliver either intervention through routine ANC, and whether women will adhere to DP for
either ISTp or IPTp. A parallel study to determine the feasibility of implementing ISTp-DP vs
IPTp-SP in routine health systems in western Kenya will help address some of these questions
(to be published elsewhere), though additional feasibility studies will be needed for IPTp-DP.
The cost effectiveness of ISTp vs IPTp and the cost of a policy change will also be published
elsewhere.
Study limitations
The experiences, perceptions and opinions of users and providers to the interventions delivered
in a trial setting in one country are not generalizable to non-trial settings. The moderator and
research team from KEMRI were likely to have been recognized by the participants as belong-
ing to the same institution that conducted the trial, resulting in a social desirability bias. There
were a limited number of women in some FGD groups, particularly in the ISTp groups (as
shown in Table 1), which may have resulted in a narrower range of viewpoints.
Conclusions
Our findings indicate that, within a trial context, IPTp-DP and ISTp-DP were generally accept-
able among both users and providers and were perceived by health providers to be potentially
valuable alternatives to IPTp-SP. Several challenges were identified, the most important of
which was adherence to DP, highlighted by women as well as health providers and trial staff.
As with SP, women will need appropriate information to promote acceptability and adherence
to DP. Health providers in general lacked confidence in the reliability of RDTs. Consequently,
any policy change from IPTp to ISTp only, i.e. not part of a hybrid strategy with IPTp, would
require a major shift in thinking among health providers through targeted training and guid-
ance on what should be done if providers suspect false negatives. Delivery of ISTp through
ANC clinics will need to take into account workload and changes in staff responsibilities. As
both interventions, particularly ISTp, will be more expensive to implement than IPTp-SP, the
sustainability issues raised by health providers will need to be addressed.
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